DNK333 5 mg + Placebo to 5 mg + DNK333 25 mg + Placebo to 25 mg + DNK333 100 mg + Placebo to 100 mg + Betamethasone 4 mg + DNK333 1mg + Placebo to 1mg
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pruritus in Patients With Atopic Dermatitis
Conditions
Pruritus in Patients With Atopic Dermatitis
Trial Timeline
Nov 1, 2009 → Jul 1, 2011
NCT ID
NCT01033097About DNK333 5 mg + Placebo to 5 mg + DNK333 25 mg + Placebo to 25 mg + DNK333 100 mg + Placebo to 100 mg + Betamethasone 4 mg + DNK333 1mg + Placebo to 1mg
DNK333 5 mg + Placebo to 5 mg + DNK333 25 mg + Placebo to 25 mg + DNK333 100 mg + Placebo to 100 mg + Betamethasone 4 mg + DNK333 1mg + Placebo to 1mg is a phase 2 stage product being developed by Novartis for Pruritus in Patients With Atopic Dermatitis. The current trial status is completed. This product is registered under clinical trial identifier NCT01033097. Target conditions include Pruritus in Patients With Atopic Dermatitis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01033097 | Phase 2 | Completed |
Competing Products
20 competing products in Pruritus in Patients With Atopic Dermatitis